Uzbekistan has introduced a new regulatory framework governing the state registration of medicinal products and medical devices. This reform modernizes the national system, aligns local requirements with international standards, and strengthens safety, transparency, and efficiency across the pharmaceutical and medical device sectors.
The new framework defines detailed procedures, evaluation mechanisms, documentation requirements, and timelines for the submission, assessment, approval, and renewal of products entering the Uzbek market. The reform applies to the entire industry, from global manufacturers and local producers to importers, distributors, authorized representatives, and expert organizations.
Below is an in-depth overview designed for industry professionals, regulatory specialists, and companies planning to register medicinal products and medical devices in Uzbekistan.
Scope of Regulation and Key Stakeholders
The new rules apply widely across the pharmaceutical and medical device ecosystem. They cover manufacturers, marketing authorization holders, authorized representatives, importers, distributors, and expert institutions responsible for conducting evaluations. The Center for Pharmaceutical Product Safety acts as the primary body handling registration reviews and final decisions.
This broad applicability ensures a unified regulatory approach and establishes higher compliance expectations for all market participants.
Two Registration Pathways: General Procedure and Recognition Procedure
The regulation introduces two distinct pathways for registration: the general procedure and the recognition procedure.
The general procedure is the standard route for most medicinal products and medical devices. It includes submission of a complete dossier in ICH CTD format, GMP verification, laboratory testing, and multi-stage expert evaluation covering quality, safety, and efficacy. Several specialized examinations are performed, including pharmaceutical, toxicological, clinical (if applicable), and analytical testing of samples. Cumulative review timelines can extend up to approximately 210 days.
The recognition procedure is an accelerated pathway for products already approved by trusted global regulatory authorities. Products authorized by WHO Listed Authorities (WLA) or regulators assessed at Maturity Level 4 (ML-4) under the WHO benchmarking system qualify for this route. By recognizing decisions of internationally stringent authorities, Uzbekistan can ensure faster access to innovative and high-priority therapies.
Priority Registration Categories
The regulation introduces a prioritization mechanism for certain therapeutic categories. Priority status may be granted to products that have no registered analogues in Uzbekistan, orphan drugs for rare diseases, medicines with high domestic demand confirmed by the Ministry of Health, and the first generic equivalents of original products.
This mechanism helps accelerate the availability of critical medicines and supports public health needs.
Documentation Requirements and Structure of the Registration Dossier
The new requirements emphasize alignment with international documentation standards. The dossier must be prepared in ICH CTD format and include administrative documents, manufacturing and quality data, stability studies, packaging information, non-clinical and clinical evidence, and samples for laboratory testing.
Required materials include manufacturing licenses, GMP certificates, product specifications, analytical methods, validation reports, toxicological profiles, clinical trial results or bioequivalence studies (for generics), and full labeling samples. Any missing or inconsistent information may suspend the review process.
Stages of Expert Evaluation
The evaluation system consists of several interconnected stages to ensure the safety, efficacy, and quality of medicinal products and medical devices. These stages include:
This structured approach enhances scientific rigor and transparency across the evaluation process.
Grounds for Refusal of Registration
Registration may be denied for multiple reasons, including incomplete or inaccurate documents, unreliable or contradictory data, failure to demonstrate safety or efficacy, non-compliance with GMP or labeling standards, negative laboratory results, or an unfavorable risk–benefit profile. These provisions ensure that only safe and high-quality products enter the market.
Duration, Renewal, Suspension, and Revocation of Registration
Each registration certificate is valid for five years. Renewal requires submission of an updated dossier confirming continued compliance with quality and safety requirements.
Registration may be suspended or canceled due to safety concerns, manufacturing violations, quality defects, falsified documents, or failure to meet pharmacovigilance obligations. The regulation provides authorities with strong tools to oversee post-market compliance.
Regulation of Medical Devices
The regulation also introduces a comprehensive system for the registration of medical devices. Key aspects include risk-based classification, conformity assessment, technical documentation requirements, laboratory testing of materials and components, and verification of labeling and user information. This unified regulatory approach strengthens oversight across all types of medical technologies.
Practical Impact on Market Participants
The reform has major implications for the pharmaceutical and medical device industries:
Overall, the updated regulatory system creates a more transparent, scientifically grounded, and efficient environment for companies operating in Uzbekistan.
The new regulation governing the registration of medicinal products and medical devices marks a substantial step forward for Uzbekistan’s healthcare and pharmaceutical sectors. It introduces modern registration pathways, clear documentation standards, extensive expert evaluations, a robust recognition mechanism, and stronger post-market oversight.
These reforms support patient safety, improve access to high-quality medicines, and provide a stable regulatory foundation for domestic and international companies. As Uzbekistan continues to modernize its healthcare system, this new framework represents a major milestone in aligning with global best practices.